Radiolabeled Monoclonal Antibody Therapy After Radiation Therapy in Treating Patients With Primary Brain Tumors
Completed · Phase 1
Conditions studied: Brain and Central Nervous System Tumors, Neuroblastoma
In brief
RATIONALE: Monoclonal antibodies can locate tumor cells and deliver tumor-killing substances, such as radioactive iodine, to them without harming normal cells. PURPOSE: Phase I trial to study the effectiveness of radiolabeled monoclonal antibody after radiation therapy in treating patients with newly diagnosed primary brain tumors that can be surgically resected.
Key facts
- Study ID
- NCT00003484
- Run by
- Darell D. Bigner, MD, PhD
- People needed
- 21
- Starts
- 1997-09-01
- Expected to finish
- 2010-03-01
- Last updated by the study team
- 2015-04-23
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Duke Comprehensive Cancer Center — Durham, North Carolina, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.